Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia Patients
NCT05899543 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-06-12
Summary
This research study aims to address the limited understanding of the challenges faced by specific demographic groups of chronic lymphocytic leukemia patients in their participation in clinical trials.
This trial will scrutinize the experiences of patients diagnosed with chronic lymphocytic leukemia as they take part in a separate medical intervention clinical trial. The focus will be on tracking the rates of completion and withdrawal among these individuals.
It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future chronic lymphocytic leukemia patients.
Conditions
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-31
- Primary Completion
- 2025-07-31
- Completion
- 2026-07-31
Countries
- United States
Study Locations
More Related Trials
-
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older
NCT00535873 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
NCT01649791 ·Status: TERMINATED ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
NCT00774345 ·Status: COMPLETED ·Phase: PHASE3
-
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT00439231 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction
NCT01578954 ·Status: COMPLETED ·Phase: PHASE1
-
Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia
NCT00006097 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01868893 ·Status: COMPLETED ·Phase: PHASE2
-
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT05143996 ·Status: RECRUITING ·Phase: PHASE1
-
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00536341 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
NCT02146924 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation
NCT00428233 ·Status: COMPLETED ·Phase: PHASE1
-
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
NCT01361711 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia
NCT01338974 ·Status: COMPLETED
-
Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia
NCT00514696 ·Status: COMPLETED ·Phase: PHASE2
-
informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
NCT02582879 ·Status: COMPLETED
-
AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
NCT00321724 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
NCT00751296 ·Status: TERMINATED ·Phase: PHASE2
-
Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia
NCT00005829 ·Status: COMPLETED ·Phase: PHASE2
-
Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
NCT05893836 ·Status: COMPLETED
-
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
NCT05672355 ·Status: SUSPENDED ·Phase: PHASE2
-
Chronic Lymphocytic Leukemia Responds to Dermal Chelation
NCT03495492 ·Status: UNKNOWN ·Phase: NA
-
Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
NCT00126893 ·Status: TERMINATED ·Phase: PHASE1
-
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
NCT00003910 ·Status: TERMINATED ·Phase: PHASE2
-
Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01246622 ·Status: COMPLETED ·Phase: PHASE1
-
Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00593944 ·Status: COMPLETED ·Phase: PHASE1